Theracos, Inc.

Jordan Mechanic

Brian Seed

Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor Mantagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist. The preferential muscarinic acetylcholine receptor Mantagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor Mantagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist.

[object Object]

Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor Mantagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor Mantagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor Mantagonist.

The present invention provides methods of treating, reducing, preventing, or inhibiting symptoms of diabetes and/or lowering plasma levels of HbA1c by co-administration of therapeutic or subtherapeutic doses of telenzepine and sertraline to a subject in need thereof.

Growing community of inventors

Sunnyvale, CA, United States of America

Jordan Mechanic